Duke Receives $10 Million to Continue Developing Blood-Based Radiation Test

Duke has received a $10.4 million contract from the Biomedical Advanced Research and Development Authority (BARDA), to continue research into the development of a blood test to measure radiation exposure.

The test, which is now being developed under the leadership of Nelson Chao, MD, MBA, chief of the Division of Hematologic Malignancies and Cellular Therapy, builds on previous research performed by the Duke Cancer Institute’s Holly Dressman, PhD, Joseph E. Lucas, PhD, and John Chute, MD.

To learn more about this award, read the full press release from Duke Medicine News and Communications.